A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

PURPOSE: This Phase I study assessed whether food influences the rate and extent of selumetinib absorption in patients with advanced solid malignancies and determined the safety, tolerability, and pharmacokinetic (PK) profile of selumetinib and its active metabolite N-desmethyl-selumetinib in fed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Leijen, Suzanne, Soetekouw, Patricia M. M. B., Jeffry Evans, T. R., Nicolson, Marianne, Schellens, Jan H. M., Learoyd, Maria, Grinsted, Lynda, Zazulina, Victoria, Pwint, Thinn, Middleton, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220813/
https://www.ncbi.nlm.nih.gov/pubmed/21953275
http://dx.doi.org/10.1007/s00280-011-1732-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220813/
https://www.ncbi.nlm.nih.gov/pubmed/21953275
http://dx.doi.org/10.1007/s00280-011-1732-7

Ejemplares similares